Your browser doesn't support javascript.
loading
Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case-control study.
Trotta, Giulia; Rodriguez, Victoria; Quattrone, Diego; Spinazzola, Edoardo; Tripoli, Giada; Gayer-Anderson, Charlotte; Freeman, Tom P; Jongsma, Hannah E; Sideli, Lucia; Aas, Monica; Stilo, Simona A; La Cascia, Caterina; Ferraro, Laura; La Barbera, Daniele; Lasalvia, Antonio; Tosato, Sarah; Tarricone, Ilaria; D'Andrea, Giuseppe; Tortelli, Andrea; Schürhoff, Franck; Szöke, Andrei; Pignon, Baptiste; Selten, Jean-Paul; Velthorst, Eva; de Haan, Lieuwe; Llorca, Pierre-Michel; Rossi Menezes, Paulo; Del Ben, Cristina M; Santos, Jose Luis; Arrojo, Manuel; Bobes, Julio; Sanjuán, Julio; Bernardo, Miquel; Arango, Celso; Kirkbride, James B; Jones, Peter B; Richards, Alexander; Rutten, Bart P; Van Os, Jim; Austin-Zimmerman, Isabelle; Li, Zhikun; Morgan, Craig; Sham, Pak C; Vassos, Evangelos; Wong, Chloe; Bentall, Richard; Fisher, Helen L; Murray, Robin M; Alameda, Luis; Di Forti, Marta.
Afiliação
  • Trotta G; Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Rodriguez V; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Quattrone D; Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Spinazzola E; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Tripoli G; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Gayer-Anderson C; Health Service and Population Research, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.
  • Freeman TP; University of Bath Department of Pharmacy and Pharmacology: University of Bath Department of Life Sciences, Bath, UK.
  • Jongsma HE; PsyLife Group, Division of Psychiatry, University College London, London, UK.
  • Sideli L; Department of Human Science, LUMSA University, Rome, Italy.
  • Aas M; Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Stilo SA; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • La Cascia C; University of Palermo Department of Biomedicine Neuroscience and Advanced Diagnostics: Universita degli Studi di Palermo Dipartimento di Biomedicina Neuroscienze e Diagnostica avanzata, Palermo, Italy.
  • Ferraro L; University of Palermo Department of Biomedicine Neuroscience and Advanced Diagnostics: Universita degli Studi di Palermo Dipartimento di Biomedicina Neuroscienze e Diagnostica avanzata, Palermo, Italy.
  • La Barbera D; University of Palermo Department of Biomedicine Neuroscience and Advanced Diagnostics: Universita degli Studi di Palermo Dipartimento di Biomedicina Neuroscienze e Diagnostica avanzata, Palermo, Italy.
  • Lasalvia A; Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.
  • Tosato S; Section of Psychiatry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy.
  • Tarricone I; University of Bologna Department of Medical and Surgical Sciences: Universita degli Studi di Bologna Dipartimento di Scienze Mediche e Chirurgiche, Bologna, Italy.
  • D'Andrea G; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Tortelli A; Establissement Public de Sante, Maison Blanche, France.
  • Schürhoff F; Univ Paris Est Creteil (UPEC), AP-HP, Hopitaux Universitaires 'H. Mondor', DMU IMPACT, INSERM, IMRB, Translational Neuropsychiatry, Fondation FondaMental, F-94010 Creteil, France.
  • Szöke A; Univ Paris Est Creteil (UPEC), AP-HP, Hopitaux Universitaires 'H. Mondor', DMU IMPACT, INSERM, IMRB, Translational Neuropsychiatry, Fondation FondaMental, F-94010 Creteil, France.
  • Pignon B; Univ Paris Est Creteil (UPEC), AP-HP, Hopitaux Universitaires 'H. Mondor', DMU IMPACT, INSERM, IMRB, Translational Neuropsychiatry, Fondation FondaMental, F-94010 Creteil, France.
  • Selten JP; Institute for Mental Health, GGZ Rivierduinen, Leiden, The Netherlands.
  • Velthorst E; Mount Sinai School of Medicine Department of Psychiatry: Icahn School of Medicine, New York, NY, USA.
  • de Haan L; Early Psychosis Section, Department of Psychiatry, Amsterdam UMC, Amsterdam, The Netherlands.
  • Llorca PM; EA 7280 Npsydo, Universite Clermont Auvergne, Clermont-Ferrand, France.
  • Rossi Menezes P; Department of Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
  • Del Ben CM; Department of Neuroscience and Behaviour, Division of Psychiatry, Ribeirao Preto Medical School, University of São Paulo, São Paulo, Brazil.
  • Santos JL; Department of Psychiatry, Hospital 'Virgen de la Luz', Cuenca, Spain.
  • Arrojo M; Department of Psychiatry, Psychiatric Genetic Group, Instituto de Investigation Sanitaria de Santiago de Compostela, Complejo Hospitalario Universitario de Santiago de Compostela, Spain.
  • Bobes J; Department of Medicine, Psychiatry Area, Universidad de Oviedo, ISPA, INEUROPA, CIBERSAM, Oviedo, Spain.
  • Sanjuán J; Department of Psychiatry, Centro de Investigation Biomedica en Red de Salud Mental, School of Medicine, Universidad de Valencia, Spain.
  • Bernardo M; Barcelona Clinic Schizophrenia Unit, Hospital Clinic, Department of Medicine, Neuroscience Institute, University of Barcelona, Institute d'investigations Biomediques, August Pi I Sunyer, Centro de Investigation Biomedica en Red de Salud Mental, Barcelona, Spain.
  • Arango C; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Maranon, School of Medicine, Universidad Complutense, ISGM, CIBERSAM, Madrid, Spain.
  • Kirkbride JB; PsyLife Group, Division of Psychiatry, University College London, London, UK.
  • Jones PB; CAMEO Early Intervention Service, Cambridgeshire and Peterborough National Health Service Foundation Trust, Cambridge, England.
  • Richards A; Division of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
  • Rutten BP; Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands.
  • Van Os J; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Austin-Zimmerman I; Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Li Z; Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Morgan C; Health Service and Population Research, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.
  • Sham PC; Hong Kong University: University of Hong Kong, Hong Kong.
  • Vassos E; Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Wong C; Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Bentall R; The University of Sheffield Department of Psychology, Sheffield, UK.
  • Fisher HL; Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Murray RM; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Alameda L; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Di Forti M; Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Psychol Med ; 53(15): 7375-7384, 2023 Nov.
Article em En | MEDLINE | ID: mdl-38078747
ABSTRACT

BACKGROUND:

Childhood adversity and cannabis use are considered independent risk factors for psychosis, but whether different patterns of cannabis use may be acting as mediator between adversity and psychotic disorders has not yet been explored. The aim of this study is to examine whether cannabis use mediates the relationship between childhood adversity and psychosis.

METHODS:

Data were utilised on 881 first-episode psychosis patients and 1231 controls from the European network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI) study. Detailed history of cannabis use was collected with the Cannabis Experience Questionnaire. The Childhood Experience of Care and Abuse Questionnaire was used to assess exposure to household discord, sexual, physical or emotional abuse and bullying in two periods early (0-11 years), and late (12-17 years). A path decomposition method was used to analyse whether the association between childhood adversity and psychosis was mediated by (1) lifetime cannabis use, (2) cannabis potency and (3) frequency of use.

RESULTS:

The association between household discord and psychosis was partially mediated by lifetime use of cannabis (indirect effect coef. 0.078, s.e. 0.022, 17%), its potency (indirect effect coef. 0.059, s.e. 0.018, 14%) and by frequency (indirect effect coef. 0.117, s.e. 0.038, 29%). Similar findings were obtained when analyses were restricted to early exposure to household discord.

CONCLUSIONS:

Harmful patterns of cannabis use mediated the association between specific childhood adversities, like household discord, with later psychosis. Children exposed to particularly challenging environments in their household could benefit from psychosocial interventions aimed at preventing cannabis misuse.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Esquizofrenia / Cannabis / Experiências Adversas da Infância Limite: Child / Humans Idioma: En Revista: Psychol Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Esquizofrenia / Cannabis / Experiências Adversas da Infância Limite: Child / Humans Idioma: En Revista: Psychol Med Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido